Letter | Published:

Reduction of atherosclerosis in mice by inhibition of CD40 signalling

Nature volume 394, pages 200203 (09 July 1998) | Download Citation

Subjects

Abstract

Increasing amounts of evidence support the involvement of inflammation and immunity in atherogenesis1,2,3,4 but mediators of communication between the major cell types in atherosclerotic plaques are poorly defined. Cells in human atherosclerotic lesions express the immune mediator CD40 and its ligand CD40L (also known as CD154 or gp39)5. The interaction of CD40 with CD40L figures prominently in both humoral and cell-mediated immune responses6. CD40L-positive T cells accumulate in atheroma5, and, by virtue of their early appearance, persistence and localization at sites of lesion growth and complication, activated T cells may coordinate important aspects of atherogenesis7,8,9. Interruption of CD40L–CD40 signalling by administration of an anti-CD40L antibody limits experimental autoimmune diseases such as collagen-induced arthritis, lupus nephritis, acute or chronic graft-versus-host disease, multiple sclerosis and thyroiditis10,11,12,13,14. Ligation of CD40 on atheroma-associated cells in vitro activates functions related to atherogenesis, including induction of pro-inflammatory cytokines5, matrix metalloproteinases15,16, adhesion molecules17,18,19 and tissue factor16,20. However, the role of CD40 signalling in atherogenesis in vivo remains unknown. Here we determine whether interruption of CD40 signalling influences atherogenesis in vivo in hyperlipidaemic mice. Treatment with antibody against mouse CD40L limited atherosclerosis in mice lacking the receptor for low-density lipoprotein that had been fed a high-cholesterol diet for 12 weeks. This antibody reduces the size of aortic atherosclerotic lesions by 59% and their lipid content by 79%. Furthermore, atheroma of mice treated with anti-CD40L antibody contained significantly fewer macrophages (64%) and T lymphocytes (70%), and exhibited decreased expression of vascular cell adhesion molecule-1. These data support the involvement of inflammatory pathways in atherosclerosis and indicate a role for CD40 signalling during atherogenesis in hyperlipidaemic mice.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature 362, 801–809 (1993).

  2. 2.

    , Conner Memorial Lecture. Mechanisms leading to myocardial infarction: insights from studies of vascular biology. Circulation 90, 2126–2146 (1996).

  3. 3.

    , , & The pathogenesis of coronary artery disease and the acute coronary syndromes. N. Engl. J. Med. 326, 242–250 (1992).

  4. 4.

    Localization of T lymphocytes and macrophages in fibrous and complicated human atherosclerotic plaques. Arteriosclerosis 72, 135–141 (1988).

  5. 5.

    Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc. Natl Acad. Sci. USA 94, 1931–1936 (1997).

  6. 6.

    , , , & Immune regulation by CD40 and its ligand gp39. Annu. Rev. Immunol. 14, 591–617 (1996).

  7. 7.

    , & Evidence for a local immune response in atherosclerosis. Am. J. Pathol. 149, 359–366 (1996).

  8. 8.

    , & Immunology of atherosclerosis: the promise of mouse models. Am. J. Pathol. 149, 351–357 (1996).

  9. 9.

    & Tlymphocytes in aortic and coronary intimas. Their potential role in atherogenesis. Am. J. Pathol. 130, 369–375 (1988).

  10. 10.

    Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40. Science 261, 1328–1330 (1993).

  11. 11.

    , , & Interaction between CD40 and its ligand gp39 in the development of murine lupus nephritis. J. Immunol. 154, 1470–1480 (1995).

  12. 12.

    Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381, 434–438 (1996).

  13. 13.

    CD40-CD40 ligand interactions in experimental allergic encephalomyelitis and multiple sclerosis. Proc. Natl Acad. Sci. USA 93, 2499–2504 (1996).

  14. 14.

    , & Suppression of murine thyroiditis via blockade of the CD40-CD40L interaction. Immunity 90, 421–426 (1997).

  15. 15.

    Regulation of matrix metalloproteinase expression in human vascular smooth muscle cells by T lymphocytes: a role for CD40 signaling in plaque rupture? Circ. Res. 81, 448–454 (1997).

  16. 16.

    , , , & Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40. Induction of collagenase, stromelysin, and tissue factor. Circulation 96, 396–399 (1997).

  17. 17.

    , , , & CD40 on human endothelial cells: inducibility by cytokines and functional regulation of adhesion molecule expression. Proc. Natl Acad. Sci. USA 92, 4342–4346 (1995).

  18. 18.

    Functional interaction of T cells with endothelial cells: the role of D40L-CD40-mediated signals. J. Exp. Med. 182, 1857–1864 (1995).

  19. 19.

    Expression of functional CD40 by vascular endothelial cells. J. Exp. Med. 182, 33–40 (1995).

  20. 20.

    , & CD40 signaling in vascular cells: a key role in atherosclerosis? Atherosclerosis (in the press).

  21. 21.

    Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. J. Clin. Invest. 92, 883–893 (1993).

  22. 22.

    Comparative effects of precisely defined semipurified diets supplemented with lipid, cholesterol, and sodium cholate on serum-lipids and aortic atherosclerosis LDL. FASEB J. 11, A154 (1997).

  23. 23.

    CD40/CD40 ligand interactions are required for T cell-dependent production of interleukin-12 by mouse macrophages. Eur. J. Immunol. 26, 370–378 (1996).

  24. 24.

    Blockade of the CD40-CD40L pathway potentiates the capacity of donor-derived dendritic cell progenitors to induce long-term cardiac allograft survival. Transplantation 64, 1808–1815 (1997).

  25. 25.

    , , , & Diet-induced hypercholesterolemia in mice: prevention by overexpression of LDL receptors. Science 250, 1273–1275 (1990).

  26. 26.

    Absence of P-selectin delays fatty streak formation in mice. J. Clin. Invest. 99, 1037–1043 (1997).

  27. 27.

    , & Quantitation of atherosclerosis in murine models: correlation between lesions in the aortic origin and in the entire aorta, and differences in the extent of lesions between sexes in LDL receptor-deficient and apolipoprotein E-deficient mice. J. Lipid Res. 36, 2320–2328 (1995).

  28. 28.

    , , & Tand B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse. Proc. Natl Acad. Sci. USA 94, 4642–4646 (1997).

  29. 29.

    , & Lymphocyte populations in atherosclerotic lesions of ApoE−/− and LDL receptor−/− mice. Decreasing density with disease progression. Arterioscler. Thromb. Vasc. Biol. 16, 1013–1018 (1996).

Download references

Acknowledgements

We thank E Shvartz, E. Rabkin, and E. Simon-Morrissey for technical assistance; W.C. Fanslow III for providing the rat anti-mouse-CD40L antibody; and M. W. Freeman, K. J. Moore and V. Kunjathoor for assistance and discussions. This work was supported in part by grants from the NHLBI (to P. L.) and from the Fond National Suisse pour la Recherche Scientifique (to F. M.).

Author information

Author notes

    • François Mach
    •  & Uwe Schönbeck

    These authors contributed equally to this work

Affiliations

  1. *Vascular Medicine and Atherosclerosis Unit, Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 221 Longwood Avenue, Boston, Massachusetts 02115, USA

    • François Mach
    • , Uwe Schönbeck
    • , Galina K. Sukhova
    • , Elizabeth Atkinson
    •  & Peter Libby

Authors

  1. Search for François Mach in:

  2. Search for Uwe Schönbeck in:

  3. Search for Galina K. Sukhova in:

  4. Search for Elizabeth Atkinson in:

  5. Search for Peter Libby in:

Corresponding author

Correspondence to Peter Libby.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/28204

Further reading

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.